Marinus Pharmaceuticals will conduct public offering of common stock

Bookrunners Jefferies and RBC Capital Markets to assist with offering

By Devika Patel

Knoxville, Tenn., Nov. 5 – Marinus Pharmaceuticals, Inc. will price a public sale of common stock with a 30-day greenshoe, according to a prospectus supplement filed Thursday with the Securities and Exchange Commission.

Jefferies and RBC Capital Markets are the bookrunners.

Proceeds will be used for preclinical and clinical development of ganaxolone, including trials, regulatory, research and development, pre-commercial, general and administrative and manufacturing expenses and working capital and general corporate purposes.

The biopharmaceutical company is based in New Haven, Conn.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.